CPC Scientific Announces New California Peptide API Manufacturing Facility
Haryana Blog/10199067
Trending...
- ReadyCommunities Partnership of CCROA Announces National Service Awardees Who Helped Save Passengers from the Derailed Train Near Rural Mendon
- Bitcoin Mining Capacity Reaches 350 Exahashes/second
- Dancing Numbers Unveils Google Sheets QuickBooks Integration, Streamlining Data Import, Export, and Deletion
SAN JOSE, Calif. - HaryanaBlog -- CPC Scientific Inc., a leading global peptide CRDMO (Contract Research, Development, and Manufacturing Organization) has invested in a new peptide API (Active Pharmaceutical Ingredient) manufacturing site, bringing many new jobs to Rocklin, California. The 41,000 sq ft facility located at 3880 Atherton Rd, Rocklin, CA 95765 will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity and will diversify CPC Scientific's supply chain.
"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.
Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.
More on Haryana Blog
Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.
"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.
More on Haryana Blog
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).
"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.
Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.
More on Haryana Blog
- Aquia Launches Amazon Web Services (AWS) Cloud Security Assessment Offering, Pairing Automation With Deep Cloud Security Expertise
- Orbex Launches New ZERO Spread Trading Account with $1 Commission per Side
- Alpha Gold Fund Receives Recognition Of Excellence Awards
- Ohio County Commission President & Founder of the Cincinnati Black Music Walk of Fame, Alicia Reece, Announces Grand Opening of New Tourism Attraction
- New York Komedians Presents an Evening of Laughs at Broadway
Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.
"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.
More on Haryana Blog
- Redefining Professional Spaces: The Rise of Dual-Purpose Backyard Office Sheds in America
- Registration is Now Open for the 2023 CGI Integrated Care Conference
- Studeo dévoile StudAI : l'Intelligence Artificielle au service de l'éducation
- EMH Productions Announce 'Live for Liberty' Charity Concert in Los Angeles Supporting "Woman, Life, Freedom" Movement in Iran
- NEMTAC® Brings Innovation to Accreditation Industry with the Launch of Collaborative Network Built on Distributed Ledger Technology
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).
Source: CPC Scientific Inc.
0 Comments
Latest on Haryana Blog
- SafeBreak® Vascular Cleared for Pediatrics
- CartoVista unveils CartoVista Cloud 8.1, the latest in GIS web mapping platforms, at 2023 FCM Conference in Toronto
- CartoVista unveils CartoVista Cloud at the 2023 FCM Conference in Toronto
- Resurgence Wellness Unveils Revolutionary Anti-Aging Breakthroughs by Tech Pioneer Bryan Johnson
- Baked by Michela Announces Grand Opening of Bucks County, Pennsylvania Bakery
- Senco Home Services Rebuilds Tewksbury Baseball Fields
- G. Entertainment Proudly Presents The Hip-hop 50th Anniversary Concert
- Telliant Systems Names Taylor Heath, Director of Business Development
- Sage Intact Launches Native AP Bill Automation to Cut Down on Invoice Processing Time
- Avoiding the Summer Slide: Oakland-Based Children Rising To Provide Summer Enrichment Programming
- U.S. Small Business Advocate Molly Bakewell Chamberlin Selected as Mentor for Buffalo Niagara Medical Campus Innovation Community Success Program
- Make your Business Stand Out with a Memorable and Relevant Name From Namify's Company Name Generator
- Engineers honored at international conference in New Orleans
- Veterans for Trump Spokesman Admiral Charles Kubic signs onto push that DEI be removed from DOD
- Black Dog Venture Partners Acquires 20% Stake in St. Petersburg based, Woman Owned Music Discovery Platform Giggidy
- We Decode DNA Kit Named One of the Top 50 Most Innovative Products of 2023 by Innovation & Tech Today
- New Jewelry Viewing Room at Biris Jewelers
- The US Senators are Getting Satellite Phones for Security, and You Should Too
- Launch of The Who's Who Guide to Asset Tokenization
- Mensa Foundation Prize Awarded to NIH Neuroscientist